This activity was supported by Contract No. 75D30121D11240 (Task Order Nos. 75D30121F00002 and 75D30123F00024) with the Centers for Disease Control and Prevention; Contract No. HHSN263201800029I (Task Order Nos. HHSN26300007, HHSN26300008, 75N98023F00019, and 75N98023F00020) with the National Institutes of Health (National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, and Office of Science Policy); and Grant No. 1R13FD007302-01 with the U.S. Food and Drug Administration. This activity was also supported by the American Association for Cancer Research; American Cancer Society; American College of Radiology; American Society of Clinical Oncology; Amgen Inc.; Association of American Cancer Institutes; Association of American Medical Colleges; Association of Community Cancer Centers; AstraZeneca; Biogen; Bristol Myers Squibb; Burroughs Wellcome Fund; Cancer Support Community; Critical Path Institute; Eli Lilly & Co.; FasterCures, Milken Institute; Flatiron Health; Foundation for the National Institutes of Health; Friends of Cancer Research; Johnson & Johnson; Medable, Inc.; Merck; National Comprehensive Cancer Network; National Patient Advocate Foundation; New England Journal of Medicine; Novartis Oncology; Oncology Nursing Society; Partners in Health; Pfizer Inc; Sanofi; and Society for Immunotherapy of Cancer. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project.